Search
Search Results
##search.searchResults.foundPlural##
-
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
3008PDF: 1022HTML: 7503 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3786PDF: 1289HTML: 5094Incidence age-standardized rates for HL across the Mediterranean basin: 251 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1616HTML: 683PDF: 903 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4187PDF: 1223HTML: 2115Fig.1: 240Fig. 2: 131Table 1: 243Table2: 258Table 3: 236 -
HEPATITIS B AND C IN HEMATOPOIETIC STEM CELL TRANSPLANT
1040PDF: 563HTML: 747 -
ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
4197PDF: 1319HTML: 2120Table 1: 229 -
SICKLE CELL DISEASE AND VENOUS THROMBOEMBOLISM
2370PDF: 984HTML: 2302 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
3355PDF: 661Suppl. Files: 319HTML: 287 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2213PDF: 898HTML: 369 -
The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study
2579PDF: 1010HTML: 387 -
EPIDEMIOLOGY OF MALARIA IN ENDEMIC AREAS
5513PDF: 2765HTML: 49887 -
PROPHYLAXIS OF MALARIA
3114PDF: 1099HTML: 18026Figures SChwartz: 203 -
MANAGEMENT OF PORTAL VEIN THROMBOSIS IN CIRRHOTIC PATIENTS
860PDF: 577HTML: 4037 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2098PDF: 1726HTML: 808 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4080PDF: 1114HTML: 3903Untitled: 198Cneo. Fig.1: 139Untitled: 131Untitled: 156Untitled: 167 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2888PDF: 1009HTML: 642 -
ON THE VERSATILITY OF VON WILLEBRAND FACTOR
2955PDF: 1209HTML: 11424 -
DYNAMIC MONITORING OF ADAMTS 13 ACTIVITY FOR DIFFERENTIAL DIAGNOSIS ACROSS THE SPECTRUM OF SEPSIS ASSOCIATED WITH THROMBOTIC MICROANGIOPATIES Adamts 13 and Sepsis Associated with Thrombotic Thrombocytopenic Purpura
899PDF: 772HTML: 240 -
-
CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY
4416PDF: 2008HTML: 5521Table 1: 255 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1385PDF: 1132HTML: 265 -
-
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7923PDF: 2505HTML: 2139Table 1.: 268Table 2.: 274Table 3.: 258Table 4.: 252 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1654PDF: 1084HTML: 146 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2357PDF: 931HTML: 2020Fig 1 Rossi: 241 -
ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS
4438PDF: 1447HTML: 2200 -
LIVER IRON CONTENT IN INDIVIDUALS WITH LIVER IRON CONTENT IN INDIVIDUALS WITH Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS.: ROLE OF METABOLIC ALTERATIONS, HFE GENOTYPES, AND CIRRHOSIS. Β-THALASSEMIA TRAIT AND HYPERFERRITINEMIA
295PDF: 327Suppl. Files: 40HTML: 79 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2634PDF: 1780HTML: 647 -
EARLY PREDICTIVE VALUE OF PERIPHERAL INFLAMMATORY INDEX COMBINED WITH HIGH-SENSITIVITY TROPONIN T FOR SEPSIS-INDUCED CARDIOMYOPATHY Inflammatory and Troponon T in cardiomyopaty from Sepsis
380PDF: 395HTML: 178







